These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30241224)

  • 1. Variation in Adherence Measures to Imatinib Therapy.
    Yanamandra U; Malhotra P; Sahu KK; Sushma Y; Saini N; Chauhan P; Gill J; Rikhi D; Khadwal A; Prakash G; Lad D; Suri V; Kumari S; Varma N; Varma S
    J Glob Oncol; 2018 Sep; 4():1-10. PubMed ID: 30241224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
    Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.
    Jönsson S; Olsson B; Söderberg J; Wadenvik H
    Ann Hematol; 2012 May; 91(5):679-685. PubMed ID: 22048790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
    Anderson KR; Chambers CR; Lam N; Yau PS; Cusano F; Savoie ML; Sheikh N
    J Oncol Pharm Pract; 2015 Feb; 21(1):19-25. PubMed ID: 24503243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.
    de Almeida MH; Pagnano KB; Vigorito AC; Lorand-Metze I; de Souza CA
    Acta Haematol; 2013; 130(1):16-22. PubMed ID: 23363706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
    Marin D; Bazeos A; Mahon FX; Eliasson L; Milojkovic D; Bua M; Apperley JF; Szydlo R; Desai R; Kozlowski K; Paliompeis C; Latham V; Foroni L; Molimard M; Reid A; Rezvani K; de Lavallade H; Guallar C; Goldman J; Khorashad JS
    J Clin Oncol; 2010 May; 28(14):2381-8. PubMed ID: 20385986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.
    Wang R; Cong Y; Li C; Zhang C; Lin H
    Medicine (Baltimore); 2019 Apr; 98(15):e15222. PubMed ID: 30985724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.
    Noens L; Hensen M; Kucmin-Bemelmans I; Lofgren C; Gilloteau I; Vrijens B
    Haematologica; 2014 Mar; 99(3):437-47. PubMed ID: 24598855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response.
    Santoleri F; Lasala R; Ranucci E; La Barba G; Di Lorenzo R; Vetrò A; Di Bartolomeo P; Costantini A
    Acta Haematol; 2016; 136(1):45-51. PubMed ID: 27160310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of therapeutic drug monitoring and adherence to imatinib in chronic myeloid leukemia in Japan.
    Kawabe K; Nakayama T; Fukuoka N; Sakamoto Y; Goto H; Suzuki T; Koike H; Sahashi Y; Ooba N
    Int J Clin Pharmacol Ther; 2022 Nov; 60(11):469-476. PubMed ID: 35924643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
    Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
    Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
    Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
    Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia.
    Krützmann ME; Martini RR; de Souza Guterres F; Kohlrausch R; Wagner SC; Mattevi VS; Torriani MS; Fogliatto LM; Linden R; Antunes MV
    J Pharm Biomed Anal; 2023 Jan; 222():115108. PubMed ID: 36279845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to imatinib among patients attending Saskatchewan Cancer Agency Pharmacies.
    Dicus M; Lyons B; Olson C; Tran DA; Blackburn DF
    J Oncol Pharm Pract; 2015 Dec; 21(6):403-8. PubMed ID: 24903271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
    Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
    Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.